Introduction: Carcinoma cervix is the most common preventable cancer in women. Every year 122,844 women are diagnosed with cervical cancer in India, and 67,477 cases die from the disease. Secondary prevention includes screening for precancerous lesions and treating them. The Papanicolaou (Pap) smear has become the standard screening test for cervical cancer and premalignant lesions globally. Material and method: In our prospective study, the results of Pap smears obtained from 680 women were analyzed, which had been examined in between March 2013 and October 2018. The pregnancy, known and treated case of cancer cervix, woman who used local douche or antiseptic cream and woman with history of Pap smear testing was excluded from the study. The patient was placed in lithotomy position. A Cusco's bivalve speculum was introduced through the vagina. The cervix was visualized. The longer projection of the Ayre's spatula was placed in the cervix near squamocolumnar junction and rotated through 360°. An average of two smears was collected for each case. The examination results were reported according to the Bethesda III Classification System (2001). Result: Cytological examination was done in all the 680 women, 100 (14.7%) smears were reported as negative for intraepithelial lesions or malignancy (NILM), 428 (62.9%) were reported as inflammatory smear, 8 (1.1%) were reported as Low grade squamous intraepithelial lesion (LSIL), 8 (1.1%) were reported as High grade squamous intraepithelial lesion (HSIL), atypical finding in 68 (10%) bacterial vaginosis in 32(4.7%) and candidiasis in 8(1.1%). Conclusion: Pap smear testing is very safe, easy to perform, non-invasive and effective test for detecting premalignant lesions of carcinoma cervix. Thus, it helps to decrease morbidity and mortality from carcinoma cervix by treating it at early stage.